Sai Life Sciences is one of India’s fastest growing Contract Research, Development & Manufacturing Organizations. As a pure-play, full-service CRO-CDMO, it works with over a 100 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.
Over the past two decades, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. Today, it has over 2000 employees across its facilities in India, UK and USA.
In 2019, marking the completion of 20 years since inception, the company announced Sai Nxt, an organisation-wide transformation initiative and committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.
The company has since added 172 KL API & Intermediate manufacturing capacity, opened a discovery biology Lab in Cambridge, Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK and an 83,000 sq. ft. integrated research & technology facility in Hyderabad. It became the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI).
Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner